Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ERAS
#1138
Erasca, Inc. - Common Stock
19.4
9
USD
+0.02%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+1.78%
Monthly Change
+8.28%
6 month change
+46.98%
Year Change
+1125.79%
Previous Close
19.1
5
Open
19.4
9
Low
19.4
9
High
19.4
9
Volume
205
Markets
US Stock Market
Healthcare
Biotechnology
ERAS
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Q1, 26
Q2, 26
Current
Key stats
Total common shares outstanding
283.29 M
283.67 M
283.71 M
310.8 M
310.98 M
349.76 M
349.76 M
Valuation ratios
Enterprise value
317.62 M
294.12 M
548.26 M
1.08 B
4.98 B
6.37 B
6.04 B
Price to earnings ratio
-2.4
-3.18
-5.45
-8.45
-17.4
-19.28
-18.32
Price to sales ratio
172.67
130.36
201.36
361.71
1 601.5
1 857.97
1 764.77
Price to cash flow ratio
2.87
3.24
5.97
-11.05
-51.31
-55.43
-52.65
Price to book ratio
0.18
0.19
0.38
3.24
3.25
3.79
3.6
Enterprise value to EBITDA ratio
-1.86
-2.09
-3.98
-8.02
-17.35
-21.44
-20.36
Profitability ratios
Return on assets %
-0.07
-0.08
-0.07
-0.07
-0.4
-0.1
-0.1
Return on equity %
-0.08
-0.09
-0.09
-0.09
-0.47
-0.12
-0.12
Return on invested capital %
-73.6
-98.9
-101.01
-99.58
-429.36
-94.28
-94.28
Gross margin %
100
100
100
100
100
100
100
Operating margin %
-4 997.19
-5 332.17
-4 440.36
-4 592.11
-26.47 K
-6 706.9
-6 706.9
EBITDA margin %
-4 781.91
-5 122.1
-4 243.32
-4 387.46
-26.26 K
-6 506.06
-6 506.06
Net margin %
-4 343.06
-4 737.9
-3 934.7
-4 097.46
-25.84 K
-6 208.31
-6 208.31
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
12.35
11.04
10.45
10.04
9.52
8.29
8.29
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.11
-0.07
-0.08
-0.08
-0.09
-0.09
-0.33
EBIT per share
-0.12
-0.13
-0.12
-0.11
-0.62
-0.15
-1
EBITDA per share
-0.12
-0.13
-0.12
-0.11
-0.61
-0.15
-0.99
Total debt per share
—
—
—
—
—
—
—
Cash per share
1.08
1.36
1.28
1.21
1.34
1.23
1.23
Net current asset value per share
1.11
1.1
1.06
1.01
0.83
0.89
0.89
Tangible book value per share
1.41
1.31
1.23
1.15
1.29
1.16
1.16
Working capital per share
1.02
1
0.96
0.91
0.75
0.79
0.79
Book value per share
1.41
1.31
1.23
1.15
1.29
1.16
1.16
News
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS)
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX)
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat (NASDAQ:TNGX)
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Erasca: "Hold" On Substantial RAS Targeting ERAS-0015 But With Two Key Risks (NASDAQ:ERAS)
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results